Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Net Income (2016 - 2025)

Karyopharm Therapeutics' Net Income history spans 14 years, with the latest figure at $90.2 million for Q4 2025.

  • For Q4 2025, Net Income rose 392.24% year-over-year to $90.2 million; the TTM value through Dec 2025 reached -$3.7 million, up 95.22%, while the annual FY2025 figure was -$3.7 million, 95.22% up from the prior year.
  • Net Income reached $90.2 million in Q4 2025 per KPTI's latest filing, up from -$33.1 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $101.2 million in Q4 2023 to a low of -$57.4 million in Q1 2021.
  • Average Net Income over 5 years is -$17.0 million, with a median of -$34.3 million recorded in 2023.
  • Peak YoY movement for Net Income: skyrocketed 1185.43% in 2021, then crashed 256.57% in 2025.
  • A 5-year view of Net Income shows it stood at $68.7 million in 2021, then tumbled by 156.06% to -$38.5 million in 2022, then skyrocketed by 362.57% to $101.2 million in 2023, then tumbled by 130.5% to -$30.9 million in 2024, then skyrocketed by 392.24% to $90.2 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Net Income are $90.2 million (Q4 2025), -$33.1 million (Q3 2025), and -$37.3 million (Q2 2025).